RESUMEN
PURPOSE: Ecchymosis is commonly encountered after upper eyelid blepharoplasty. The use of homeopathic preparations of Arnica montana, a flowering herb, has been advocated by physicians, patients, and manufacturers for reduction of postsurgical ecchymosis. The authors evaluate its efficacy after upper eyelid blepharoplasty. METHODS: A prospective, placebo-controlled, double-blind study was performed in which patients were randomly assigned to the administration of homeopathic A. montana or placebo concurrent with unilateral upper eyelid blepharoplasty followed by contralateral treatment at least 1 month later. Ecchymosis was evaluated at days 3 and 7 by rank order of severity and measurement of surface area of observable ecchymosis. RESULTS: There was no statistically significant difference in area of ecchymosis or rank order of ecchymosis severity for days 3 and 7 after treatment with A. montana versus placebo. Additionally, there was no difference in ease of recovery per patient report, and there was no difference in the rate of ecchymosis resolution. CONCLUSIONS: The authors find no evidence that homeopathic A. montana, as used in this study, is beneficial in the reduction or the resolution of ecchymosis after upper eyelid blepharoplasty.
Asunto(s)
Arnica , Blefaroplastia , Equimosis/tratamiento farmacológico , Párpados/cirugía , Fitoterapia , Complicaciones Posoperatorias , Administración Oral , Adulto , Anciano , Cápsulas , Método Doble Ciego , Equimosis/diagnóstico , Equimosis/etiología , Formularios Homeopáticos como Asunto , Humanos , Masculino , Persona de Mediana Edad , Preparaciones de Plantas/uso terapéutico , Estudios Prospectivos , Resultado del TratamientoRESUMEN
PURPOSE: To determine if bioactive glass, originally designed for craniomaxillofacial use, can be used effectively for re-pegging of hydroxyapatite orbital implants. METHODS: Over a 2-year period, 3 patients with pegged hydroxyapatite orbital implants and related complications that did not respond to conservative treatment, underwent removal of the implant pegs and/or sleeves. Peg tracts were subsequently filled with bioactive glass. RESULTS: No complications occurred in any case during 3 years of follow-up. After 2 months, 2 patients underwent successful re-drilling of the peg site and insertion of titanium pegs. Both patients were satisfied with the results. The third patient has deferred re-pegging at this time. CONCLUSION: Bioactive glass is effective for refilling old peg tracts and allowing timely re-pegging of hydroxyapatite implants.